1IA
LGND icon

1620 Investment Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

1620 Investment Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$948 Buy
+3
New +$707 ﹤0.01% 644

Other funds holding LGND

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
PM
Pembroke Management Montreal, Quebec, Canada $637M AUM 40.98% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
IP
Isthmus Partners Madison, Wisconsin $1.03B AUM 22.86% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
WC
Woodstock Corp Boston, Massachusetts $1.2B AUM 26.37% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 38.93% 1-Year Est. Return

1620 Investment Advisors's LGND Position: Q2 2026 in Review

1620 Investment Advisors opened a new position in Ligand Pharmaceuticals (LGND) in Q2 2026: 3 shares worth $948. The stake represents ﹤0.01% of the portfolio and ranks #644 among its holdings.

103 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • 1620 Investment Advisors held 3 shares of Ligand Pharmaceuticals worth $948 as of Q2 2026.
  • Ligand Pharmaceuticals was a new 1620 Investment Advisors position in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of 1620 Investment Advisors's portfolio in Q2 2026, its #644 holding.
  • 103 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on 1620 Investment Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.